RSC Advances



View Article Online

View Journal | View Issue

PAPER



Cite this: RSC Adv., 2024, 14, 36527

Received 18th May 2024 Accepted 5th November 2024 DOI: 10 1039/d4ra03674c

rsc.li/rsc-advances

Introduction 1.

Secondary metabolites are structurally varied and pharmacologically active molecules produced by fungi, thriving in hyperbaric, oligotrophic, hypersaline, and other specialized environments.^{1,2} They are common in nature, particularly naphtho-gamma-pyrones (NyPs) found in Aspergillus, Fusarium, and Penicillium.3 Their structures consist of a naphthalene and a γ -pyrone moiety, while their dimeric form is created by linking two NyPs together through a diaryl bond. The cytochrome P450 enzymes play an important role in the dimerization of NyPs based on the stereoselectivity of monomeric substrates.⁴ Aspergillus is a common genus of fungi responsible for the biosynthesis of several specialized small molecules, including fumonisins, bicoumarins, asperazines, ochratoxins, and NyPs.5 Chemists and biologists have shown particular interest in NyPs pigments because they have been widely isolated as antioxidant, antiviral, and antimicrobial agents.6

Fungal-derived steroids have shown potential benefits in reducing neurotoxicity and neuronal cell death, suggesting they may be useful in delaying the onset of dementia. Additionally, fungal steroids have been proven to prevent autoimmune diseases and chronic inflammatory diseases.7 The sterol ergosterol, produced by fungi, plays a role in maintaining membrane

Isolation, characterization and pharmacological investigations of secondary metabolites from Aspergillus ficuum via experimental and computational techniques*

Zafar Ali Shah,^a Khalid Khan, ^b *^a Tanzeel Shah,^b Nasir Ahmad^a and Asad Khan^a

Fungal metabolites are known for their broad therapeutic effects. In this context, the fungal strain of Aspergillus ficuum (FCBP-DNA-1266) was examined for its secondary metabolites and in vivo activities. This led to the isolation of naphtho-gamma-pyrone (aurasperone B) and a sterol (ergosterol), characterized using advanced spectroscopic techniques such as ¹H NMR and ¹³C NMR. The isolated metabolites were evaluated for their in vivo anti-inflammatory and analgesic activities utilizing an animal model. The study showed that both metabolites have significant pharmacological effects ($P \le 0.05$) in a dose-dependent manner. In addition, in silico analysis was employed to aid the in vivo antiinflammatory activity and the molecular docking results were in agreement with the experimental findings. For the first time, we present the pharmacological activities and 2D NMR of aurasperone B. which will shed light on the bioactive potential of secondary metabolites of Aspergillus ficuum.

> fluidity and structure.8 Beyond their structural roles, sterols have also been shown to exhibit a variety of biological activities.9

> In our ongoing search for bioactive metabolites from fungi, we have identified several potent metabolites from Aspergillus ficuum (A. ficuum). It has demonstrated numerous bioactivities, such as antimicrobial, DPPH radical scavenging, antiinflammatory, antispasmodic, and anticancer properties. The ethyl acetate extract of A. ficuum showed a significant antiinflammatory effect at a dosage of 150 mg kg⁻¹.^{10,11}

> Based on our previous investigations, we have worked on the isolation and characterization of the secondary metabolites aurasperone B and ergosterol from A. ficuum. To the best of our knowledge, this constitutes the first report on the in vivo activities of aurasperone B, specifically its anti-inflammatory and analgesic effects using a mouse model. Furthermore, the activities of both compounds were supported by in silico analysis.

2. Materials and methods

Fungal culture collection 2.1.

The First Fungi Bank of the University of Punjab in Lahore, Pakistan, provided the fungal strain A. ficuum (FCBP-DNA-1266). The Ethical Committee FAHV&S of the University of Agriculture Peshawar, Pakistan, approved in vivo studies (7196/LM/UoA).11

2.2. General experimental conditions

The ¹H NMR and ¹³C NMR spectra of both compounds were carried out using Bruker AVANCE 500 and 100 MHz, respectively, at Hussain Ejaz Research Center of Chemistry, University

^aDepartment of Chemistry, Islamia College University, Peshawar, Khyber Pakhtunkhwa, Pakistan. E-mail: drkhalidchem@yahoo.com

^bInstitute of Basic Medical Sciences, Khyber Medical University, Peshawar, Khyber Pakhtunkhwa, Pakistan

[†] Electronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d4ra03674c

of Karachi, Pakistan. TMS was used as a reference compound, while all the spectral information was obtained in deuterated solvents. 2D NMR techniques (HSQC, COSY & HMBC) were examined through Mnova Software. Column and thin layer chromatography techniques were carried out using precoated aluminum sheets with silica-gel 60 F_{254} (20 \times 20 cm, 0.2, Merck, Germany) and silica gel (200-300 mesh), respectively. The chromatographic techniques were carried out on commercial solvents after they were redistilled. For the anti-inflammatory and analgesic activities, analytical grade reagents and chemicals (Sigma Aldrich) were used.

2.3. Culture cultivation

A haemocytometer was used to count spores in a suspension of A. ficuum (FCBP-DNA-1266), containing 10^{-5} conidia per ml. This suspension was then inoculated centrally into 20 liters of medium sized potato dextrose broth (PDB), consisting of potato extract (4 g L⁻¹) and dextrose (20 g L⁻¹) in sterilized 500 mL Erlenmeyer flasks. The pH of the medium was adjusted to 5.6 \pm 0.5, and the inoculated flasks were maintained under static conditions at 28 °C for three weeks.11

2.4. Extraction & isolation

After three weeks of culture, the mycelia were removed from the broth and dried. The dried mycelia were extracted with ethyl acetate (3 \times 500 mL) and condensed by a rotary evaporator under reduced pressure. A total of 18 g of crude ethyl acetate fraction was obtained.

The ethyl acetate fraction (18 g) was subjected to column chromatography using a solvent system of chloroform and

methanol in varying ratios (10:0 to 0:10), resulting in the collection of 74 vials (Fig. 1). These vials were sorted based on polarity into four subfractions, namely A, B, C, and D. The quantity and polarity of subfractions A to D were 2.5 g (10:0), 3.7 g (9:1), 10 g (6:4), and 1.8 g (0:10), respectively. Further separation of subfraction A into two subfractions, A.1 and A.2, The subfraction A1 yielded compound 1 (25 mg) using preparative TLC with a polarity of MeOH and $CHCl_3$ (3:7). The fraction C was further divided into two subfractions, D1 and D2. The subfraction D2 upon subjection to the pencil column resulted in the isolation of compound 2 (20 mg) in a solvent system of methanol and chloroform with a polarity of 6:4.

2.5. Anti-inflammatory study

The anti-inflammatory activity of aurasperone B and ergosterol was evaluated using the carrageenan-induced paw edema test.12 The animals were separated into four groups: vehicle (5% DMSO and 1% Tween 80), vehicle + carrageenan, aspirin + carrageenan, and compounds + carrageenan. Aurasperone B and ergosterol were orally administered in three different doses of 5, 10, and 15 mg kg⁻¹. While the control group received aspirin at a dose concentration of 15 mg kg⁻¹. After an hour of administration, a 1% carrageenan solution was administered to the left hind paw in the subplantar area, and the paw thickness of the animals was measured every hour for a total of 5 h using a vernier caliper. Tween 80 was used to increase the solubility of the drug or extract. Standard aspirin and the vehicle were taken as positive and negative controls, respectively. The percentage anti-inflammatory effect was determined using the following formula:



Fig. 1 Isolation scheme of compound 1 and compound 2.

Anti-inflammatory effect (%) = $[(C_t - C_0) \text{ control} - (C_t - C_0) \text{ treated}]/(C_t - C_0) \text{ control} \times 100$

 $C_{\rm t}$ = thickness after 1–5 h C_0 = baseline paw thickness.

2.6. Analgesic study

The study evaluated the antinociceptive (pain-relieving) effects of aurasperone B and ergosterol using an abdominal constriction test induced by acetic acid.¹³ The test was conducted on animals (presumably mice or rats). Aurasperone B and ergosterol were orally administered in three different doses of 5, 10, and 15 mg kg⁻¹. The control group received diclofenac sodium at a dose concentration of 50 mg kg⁻¹, a known pain reliever, which was provided through the intraperitoneal (i.p.) route. One hour after administration, the animals were injected with 1% acetic acid at a volume-to-mass ratio of 10 ml kg⁻¹ (i.p.). The number of abdominal contractions (writhes) was counted continuously for the next 20 minutes, starting 10 minutes after the injection of acetic acid.

The percentage of antinociception was calculated for all groups using an equation. This provided an estimate of how effective the compounds were in reducing pain compared to the positive control (diclofenac sodium) and helped to determine the optimal dosage of the compound for maximum pain relief.

Antinociception (%) =
$$(1 - C_1/C_2) \times 100$$

 C_1 = number of writhes in the treated groups C_2 = number of writhes in the vehicle (5% DMSO and 1% Tween 80)

One-way ANOVA followed by Dunnett's *post hoc* test was performed using GraphPad prism package 8.0.

2.7. In silico analysis

For the molecular docking analysis, the structures of the target proteins COX1 (PDB ID: 6Y3C)¹⁴ at a resolution of 2.90 Å, and COX2 (PDB ID: 1PXX)¹⁵ at a resolution of 2.0 Å were obtained from the Protein Data Bank (https://www.rcsb.org). The acquired protein structures went through a refinement process using BIOVIA Discovery Studio 2021 v21.1.0.20298 (Dassault Systems: https://www.3ds.com). Initially, water molecules and heteroatoms were removed. The missing atoms were added to get a full and accurate protein structure. Subsequently, polar hydrogen atoms were incorporated into the protein structures. Furthermore, to facilitate an accurate representation of electrostatic interactions, Kollman charges were introduced. For the prediction of the active site pocket, CASTp server was used.¹⁶ The first Poc ID with a larger volume and surface area was selected as an active pocket. The amino acid residues comprising this active site pocket were in line with the literature and the crystallographic structure data. The grid box was positioned to cover the pocket. The resolved center coordinates of the grid box are as follows:

For COX1 (6Y3C)

Centre X: -44.7888, Y: -59.1681, Z: 11.7971

Dimensions X: 36.1706, Y: 24.1632, Z: 16.1069

For COX2 (1PXX)

Centre X: 31.5718, Y: 20.4386, Z: 15.2962

Dimensions X: 36.6058, Y: 25.8849, Z: 23.8376

Subsequently, ChemDraw software (http:// www.perkinelmer.co.uk/category/chemdraw) was employed to construct compound structures and then saved in SDF format to ensure compatibility with the docking studies. The AutoDock Vina software,17 incorporated into PyRx version 0.8,18 was used to carry out the molecular docking study. Initially, the compounds were incorporated into PyRx using the OpenBabel graphical user interface. The universal force field (UFF) was used to minimize the energy of both compounds. After that, these compounds were converted to pdbqt format to make sure the AutoDock Vina program could read them. The target proteins have been imported into PyRx and given pdbqt file extension. In order to guarantee an extensive investigation of ligand binding modalities, the exhaustiveness level was set at 24.

2.8. Toxicity prediction

The toxicity profile plays a critical role in drug design by providing essential information about the safety and potential side effects of a compound. It allows researchers to identify risks by assessing various toxicity endpoints, such as hepatotoxicity, cytotoxicity, and mutagenicity. This information guides the optimization of chemical structures, enhancing efficacy while minimizing harmful effects, ultimately leading to safer drug candidates.¹⁹ Therefore, the toxicity profiles, pharmacokinetics, median lethal dose (LD_{50} , mg kg⁻¹), and toxicity class of both compounds were evaluated using the ProTox-II online tool.²⁰ The toxicity assessment encompassed hepatotoxicity, carcinogenicity, immunotoxicity, mutagenicity, and cytotoxicity. Pharmacokinetic parameters, including CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, and CYP2E1, were also predicted.

3. Results & discussion

3.1. Identification and confirmation of aurasperone B and ergosterol

The ethyl acetate extract of the fungal strain *A. ficuum* after subjection to column chromatography yielded two secondary metabolites, a naphtho gamma pyrone named aurasperone B (1) and ergosterol (2). Compound 1 was isolated in yellowish form. The ESI⁺ calculated for aurasperone B was 607.61 [M + H]⁺. It was characterized as a dimer. The difference between the two halves of the molecules was the presence of an additional hydroxyl group. ¹³C NMR spectrum of compound 1 provided a total number of 31 peaks in its broadband spectrum. These peaks were representative of methine, methyl and quaternary carbons. The quaternary carbon peaks were assigned as δ C-3 (197.5), C-4 (107.8), C-5 (160.1), C-6 (110.2), C-7 (141.2), C-9 (153.4), C-12 (165.4), C-13 (103.1), C-14 (150.6), C-23 (100.5), C-25 (197.5), C-26 (108.3), C-27 (158.8), C-28 (111.3), C-29 (136.5), C-30 (112.6), C-31 (155.8), C-34 (163.7) and C-36 (160.6) respectively. The methine carbons were observed as δ C-8 (99.2), C-11 (104.1), C-33 (97.2) and C-35 (96.2). Four methoxy methyl groups C-18, C-20, C-40 and C-42 were attributed chemical shift values of δ 55.2, 61.63, 56.2 and 55.9 respectively. Both methyl carbons C-16 and C-38 attached to the pyran ring signaled at δ 27.5 (Table 1).

Total number of twenty-one protons was characterized from the peaks provided in ¹H NMR spectrum. The methoxymethyl protons peaks were assigned to δ 3.75 (3H, s, H-18), δ 4.02 (3H, s, H-20) and δ 3.79 (3H, s, H-39). Both methyl protons of the pyran ring signalled at δ 2.13 (3H, s, H-16) and δ 2.12 (3H, s, H-37) (Fig. 2).

The diastereotopic protons in both pyran rings were awarded to δ 2.92, 2.99 (2H, s, H-2&24). The methine protons of the aromatic rings showed their presence at δ 6.90 (1H, s, H-8), δ 6.73 (1H, s, H-11), δ 6.43 (1H, s, H-33) and δ 6.21 (1H, s H-

Table 1 ¹H NMR, and ¹³C NMR data of compound (1 and 2) in CDCl₃

Compound 1			Compound 2		
Position	$\delta_{ m H}$	δ_{C}	Position	$\delta_{ m H}$	$\delta_{ m C}$
			1	3.43, m	71.2
2	2.92, 2.99, dd	47.1	3	1.48, 1.23, m	30.6
3		197.5	4	1.27,0.99, m	36.3
4		107.8	5	2.16,1.86, dd	38.3
5		160.1	6		138.4
6		110.2	7	5.23, d	116.4
7		141.2	8	5.23, d	116.7
8	6.90, s	99.2	9		139.6
9		153.4	10	1.88, m	52.1
11	6.73, s	104.1	11	1.49, 1.40, m	21.1
12		165.4	12	1.88, m	25.6
13		103.1	13	1.08, m	54.5
14		150.6	14	1.96, m	38.8
$16-CH_3$	1.42, s	27.5	15	5.11, m	131.4
18-OCH ₃	3.80, s	55.2	16	5.1, m	129.5
20-OCH ₃	4.00, s	61.63	17	1.88, m	38.5
21-OH	14.21		18	0.85, s	18.2
22-OH	5.60		19	1.49, m	31.23
23		100.5	20	0.98, m	19.5
24	2.92,2.99, dd	47.1	21	0.98	19.1
25		197.5	22	0.84, s	19.3
26		108.3	23		41.7
27		158.8	24	1.03, m	13.5
28		111.3	25	1.15, m	37.3
29		136.5	26	0.89, m	19.3
30		112.6	27	1.79, m	43.6
31		155.8	28		34.7
33	6.43, s	97.2	29	0.93, s	14.6
34		163.7			
35	6.21, s	96.2			
36		160.6			
38-CH ₃	1.52, s	27.5			
40-OCH ₃	3.99, s	56.2			
42-OCH ₃	3.81, s	55.9			
43-OH	14.56				
44-OH	7.12				



Fig. 2 Structure of aurasperone B (1) blue arrows represent key HMBC correlations.

35). The two hydroxyl groups on the aromatic rings were noted at δ 14.21 & 14.56 (2OH, s), while the other two hydroxyl groups of the pyran ring were assigned a value of δ 5.60 & 7.12 (2OH, s).

There was no ¹H-¹H coupling between the protons which were evident from the COSY spectrum. However, long-range coupling (HMBC) between various protons with respective carbons helped in the elucidation of the given structure. The HMBC correlations of the hydroxyls OH's groups with carbonyl carbons helps in their fixation at the corresponding place. Similarly, both diastereotopic protons showed three bonds away correlations with their respective carbonyl carbons. Based on the correlations and various chemical shift values of hydrogens and carbons, the structure was characterized as aurasperone. The data agreed with literature.²¹

Compound 2 was isolated as a white powder with a molecular ion peak [M⁺] at 396.34. The broad band of ¹³C NMR spectrum showed twenty-eight carbon peaks. These peaks represented seven methylene, twelve methines, five methyl and four quaternary carbons signals. The methine peaks were observed at chemical shift values were assigned to respective carbons such as δ 71.2 (C-1), 116.4 (C-7), 116.7 (C-8), 52.1 (C-10), 54.5 (C-13), 38.8 (C-14), 131.4 (C-15), 129.5 (C-16), 38.5 (C-17), 19.5 (C-20), 13.5 (C-24) and 43.6 (C-27). The peaks for methylene carbons were found to resonate at δ 30.6 (C-3), 36.3 (C-4), 38.3 (C-5), 21.1 (C-11), 25.6 (C-12), 37.3 (C-2525) and 19.3 (C-26). The methyl signaled at δ 18.2 (C-18), 31.2 (C-19), 19.1 (C-21) and 14.6 (C-29). The quaternary carbons were awarded to δ 138.4 (C-6), 139.6 (C-9), 41.7 (C-23) and 34.7 (C-28) (Table 1) and (Fig. 3).

The ¹H NMR spectrum indicated methine signals resonated at δ 3.43 (1H, m, H1), 5.23 (1H, d, J = 1.72, H-7), 5.23 (1H, d, J =1.72, H-8), 1.08 (1H, m, H13), 1.96 (1H, m, H14), 5.11 (1H, m, H15), 5.11 (1H, m, H16), 1.88 (1H, m, H17) and 1.79 (1H, m, H27). Methylene proton signaled their position at δ 1.48 (2H, m, H3) 1.27 (2H, m, H4), 2.16, 1.88 (2H, dd, *J* = 12.32, 1.9 Hz, H-5), 1.49 (2H, m, H11), 1.88 (2H, m, H-12), 1.15 (2H, m, H24) and 0.89 (2H, m, H-26). The position of five methyl protons were located at δ 18.2 (3H, s, H-18), 0.98 (3H, s, H-20), 0.98 (3H, m, H-21), 0.84 (3H, m, H-22), 1.03 (3H, m, H-24) and 0.93 (3H, s, H-29). The data was in agreement with the literature.²²



3.2. Anti-inflammatory and analgesic activities of

aurasperone B and ergosterol

Naphtho-gamma-pyrones (NGPs) are secondary metabolites of polyketide nature. They are biosynthesized by a wide range of filamentous fungi and some higher plants.23

In this study, the anti-inflammatory and analgesic activity of aurasperone B and ergosterol was investigated in vivo and finally statistically evaluated by Dunnett's test. Aurasperone B was less significant at a dose of 5 mg kg⁻¹ ($P \le 0.05$), while no significant difference was observed between dose levels of 10 and 15 mg kg⁻¹. Subsequently, ergosterol was moderately active $(P \le 0.002)$ at a dose level of 10 mg kg⁻¹ and significantly less active ($P \le 0.03$) at a dose level of 20 mg kg⁻¹ (Table 2).

The effect of both secondary metabolites was evident that they can have anti-inflammatory potential (Fig. 4 and S8⁺).

The potential use of dimeric NyPs in agriculture and medicine has drawn the attention of many researchers to this class of compounds. Aurasperone B is the precursor of aurasperone A and other congeners.24 Aurasperone B is dextrorotatory and is a dihydrate of aurasperone A, which itself is levorotatory.²⁵ NyPs are thought to be defense metabolites produced under stressful conditions and serve as non-toxic agents for fungal defense against predators.

Various bioactivities have been reported from NyPs such as antioxidant, antitumor and antimicrobial.24 Recently, mutagenic, hepatoprotective and anxiety-related disorders have been treated by polyketides.²⁶ At a dose of 50 mg kg⁻¹ by intraperitoneal injection in rats, significant central nervous disorders were induced.27

Similarly, several ergostane-type metabolites have been isolated from fungi and plants. They have shown potential for various biological activities. Ergosterol has been used for the treatment of various diseases such as those with anticancer potential in the lungs, breast and colon.²⁸ Similarly, various studies have presented its pharmacological potential.29

In analgesic activity, aurasperone B at dose concentrations of 5, 10, and 15 mg kg⁻¹, the percentage inhibition significantly increases with time duration from 1 h to 3 h. Overall, the percentage inhibition among doses and positive control was highly significant ($P \leq 0.04$), while the highest percentage inhibition was recorded at 15 mg kg⁻¹ ($P \le 0.05$) after 3 h of study compared to standard diclofenac sodium. In the case of ergosterol, a similar response was noted between its various doses and the positive control during 3 h study. Although the effect was as significant as that of aurasperone B, the significance among doses of ergosterol was 10 mg kg⁻¹ ($P \le 0.02$), 20 mg kg⁻¹ ($P \le 0.03$) and 30 mg kg⁻¹ ($P \le 0.04$) compared to standard (Table 3). Moreover, the highest percentage of inhibition (23.08 \pm 0.32) was observed at 30 mg kg⁻¹ for ergosterol after 3 h of study.

The results indicated the positive potential of both secondary metabolites and needed to be included in the drug discovery program (Fig. 5 and S9[†]).

Recently, an isomer of aurasperone D was investigated in vitro against SARS CoV-2. An efficient potential was shown by aurasperone A against that virus.²⁴ The fungus Aspergillus niger produces aurasperone B, a dimeric NyPs with strong antioxidant properties and moderate toxicity against various cancer cell lines and brine shrimp.^{21,30-32} Dimeric pyrones with a similar structure have also been reported in other species of fungi.33-35 It is suggested that further investigation of these metabolites may help in the development of new drugs.

3.3. Molecular docking study

Cyclooxygenases (COX1 and COX2) are crucial enzymes in inflammation, converting arachidonic acid into prostaglandins and thromboxanes. COX1 plays a supportive role by maintaining normal physiological functions rather than directly

Table 2	Anti-inflammatory activity	of aurasperone l	3 and ergosterol
---------	----------------------------	------------------	------------------

		Percentage inhibition after different time intervals ^a				
Treatments	Conc. (mg kg $^{-1}$)	1 h	2 h	3 h	4 h	5 h
Aspirin	10	68.48 ± 1.87	$\textbf{78.8} \pm \textbf{0.76}$	89.67 ± 1.51	95.11 ± 1.43	98.91 ± 1.21
Aurasperone B	5	60 ± 1.23	63.64 ± 1.21	66.67 ± 0.98	77.58 ± 1.23	77.58 ± 0.44
	10	61.11 ± 1.25	66.67 ± 1.126	72.84 ± 0.76	79.01 ± 1.01	79.01 ± 0.32
	15	66.87 ± 1.98	72.29 ± 1.56	78.92 ± 0.43	84.94 ± 1.04	84.94 ± 0.12
Ergosterol	10	54.04 ± 2.12	59.01 ± 1.43	66.46 ± 1.46	74.53 ± 1.21	74.53 ± 0.98
	20	54.09 ± 2.18	59.75 ± 1.72	67.92 ± 1.22	74.84 ± 1.04	74.84 ± 1.34
	30	58.9 ± 2.45	65.64 ± 1.42	72.39 ± 1.08	79.75 ± 0.56	79.75 ± 1.33

^a Data shown is processed through one-way ANOVA, followed by Dunnett's test.





Fig. 4 Anti-inflammatory activity of aurasperone B & ergosterol.

Table 3 Analgesic activity of aurasperone B and ergosterol

Treatments	Concentration (mg kg ⁻¹)	% inhibition 1 h	% inhibition 2 h	% inhibition 3 h
Diclofenac sodium	10	61.96 ± 1.21	93.95 ± 1.551	95.8 ± 0.76
Aurasperone B	5	14.53 ± 1.04	22.48 ± 0.98	25.65 ± 1.21
-	10	28.14 ± 0.56	40.6 ± 0.76	45.1 ± 1.13
	15	35.71 ± 0.43	52.48 ± 0.43	55.32 ± 1.10
Ergosterol	10	7.67 ± 1.43	17.49 ± 1.23	19.93 ± 0.44
0	20	13.8 ± 1.72	20.28 ± 1.01	23.08 ± 0.32
	30	23.9 ± 1.42	28.97 ± 1.04	33.15 ± 0.12



mediating the inflammatory response. It is constitutively expressed in many tissues and produces prostaglandins that protect the gastric lining, regulate blood flow in the kidneys, and promote platelet aggregation. In contrast, COX2 is induced during inflammation, generating prostaglandins that promote vasodilation, increase vascular permeability, and attract immune cells, leading to redness, swelling, and pain. Additionally, prostaglandins sensitize pain receptors and regulate fever.³⁶ Therefore, these two enzymes were selected for docking analysis against aurasperone B and ergosterol. The docking details are provided below.

3.3.1. Interaction analysis of COX1. Relative to compound 2, compound 1 interacted with the COX1 protein more favorably. Compound 1 had a binding energy of -7.1 kcal mol⁻¹, while compound 2 displayed -7.0 kcal mol⁻¹ (Table 4).

Compound 1 exhibited seven interactions with COX1's active site. These interactions include two Pi–sigma bonds with Val447, a H-bond and carbon–hydrogen bond with His446, two Pi–alkyl bonds with residues Leu408, Leu295, and one Pi-donor H-bond with Gln203 (Fig. 6a and b). A total of five interactions were formed by compound 2. Four alkyl bonds were involved in these interactions: two with Val447 and two with Ile444. In addition, one Pi–alkyl bond was formed with His388 (Fig. 6c and d). Similarly, aspirin demonstrated a binding energy of -6.2 kcal mol⁻¹ with the COX1 protein, forming five distinct interactions. These include two C–H bonds with residues His386 and His388, an amide–Pi stacked interaction with Ala202, a Pi–sulfur interaction with Met391, and a van der Waals interaction with Gln203 (Fig. 6e and f).

Table 4	Interaction details o	f compound 1 , compou	nd 2 , and aspirin with	COX1 and COX2 proteins
---------	-----------------------	------------------------------	--------------------------------	------------------------

Proteins	Compounds	Binding energy (kcal mol ^{-1})	Interacting residues	Nature of interaction
COX1 (6Y3C)	Compound 1	-7.1	His446	H-bond
	-		His446	C–H bond
			Val447	Pi–sigma bond
			Val447	Pi–sigma bond
			Leu408	Pi–alkyl bond
			Leu295	Pi–alkyl bond
			Gln203	Pi-donor H-bond
	Compound 2	-7.0	Val447	Alkyl bond
			Val447	Alkyl bond
			Ile444	Alkyl bond
			Ile444	Alkyl bond
			His388	Pi–alkyl bond
	Aspirin	-6.2	His388	C–H bond
	-		His386	C-H bond
			Ala202	Amide–Pi-stacked
			Met391	Pi–sulfur
			Gln203	van der Waals
COX2 (1PXX)	Compound 1	-8.4	Gln369	H-bond
	-		Ser126	C–H bond
			Pro127	C–H bond
			Arg61	C–H bond
			Lys532	Alkyl bond
			Phe371	Pi–alkyl bond
			Arg61	Pi–alkyl bond
			Arg61	Pi-alkyl bond
	Compound 2	-7.6	Arg61	Alkyl bond
	-		Arg61	Alkyl bond
	Aspirin	-6.1	Ser530	H-bond
	-		Gly526	Amide–Pi-stacked
			Val523	Pi–alkyl
			Leu353	Pi-alkyl
			Ala527	Pi–alkyl

The secondary structural components of COX1 indicate an epidermal growth factor, membrane binding domain, and catalytic domain. Two important sites in protein structure are the substrate site, where substrates attach, and the heme site, where the heme molecule required for COX1 function interacts.¹⁴ Both of our compounds bind with and block these key regions, so disrupting the normal activity of the COX1 enzyme. Compounds **1** and **2** interacted with residues His446, Val447, Ile44, and Leu408 of the heme site, presumably blocking it. Compound **2** also interacted with His388 at the substrate site, occupying the substrate regions and making it harder for a substrate to attach to the substrate site.

3.3.2. Interaction analysis of COX2. Compound 1 had a high binding energy of -8.4 kcal mol⁻¹ (Table 4) and a total of eight interactions with the COX2 protein active site. Specifically, it formed one H-bond with Gln369. Additionally, it made three carbon–hydrogen bonds with Ser126, Pro127, and Arg61, and three Pi–alkyl bonds with residue Phe371, and two with Arg61. A single alkyl bond was also noted with Lys532 (Fig. 7a and b). Compound 2 exhibited a binding energy of -7.6 kcal mol⁻¹ and formed two alkyl bonds with Arg61 (Fig. 7c and d). The COX2 active site is essential to its activity. Previously, it was studied and inhibited by numerous compounds in several studies.¹⁵ In our analysis, compound 1 interacted with critical residues such

as Lys532, Ser126, and Phe371, all of which are in close vicinity of the active site, demonstrating that compound **1** has the ability to inhibit it. Similarly, aspirin exhibited a binding energy of -6.1 kcal mol⁻¹ with the COX2 protein, forming five key interactions. These include three Pi–alkyl bonds with Val523, Leu353, and Ala527, as well as a hydrogen bond with Ser530 and an amide–Pi stacked interaction with Gly526 (Fig. 7e and f).

Experimental results indicate that both compound **1** and compound **2** have the potential to reduce inflammation; however, their anti-inflammatory effects are weaker compared to the standard drug aspirin. Additionally, compound **1** demonstrates a more pronounced anti-inflammatory effect than compound **2**. In the *in silico* study, similar findings were observed, with compound **1** showing a strong binding affinity to both COX1 and COX2 enzymes compared to compound **2**. Conversely, aspirin exhibited a lower binding affinity to COX1 and COX2 than either compound, which is not consistent with the experimental data. Nevertheless, the overall docking results support the experimental findings.

3.4. Toxicity and pharmacokinetics prediction

The five toxicity endpoints and pharmacokinetic properties of both compounds were predicted using computational tools,



Fig. 6 2D and 3D representations summarize the results of the interaction analysis for the (a and b) COX1–compound 1 complex, (c and d) COX1–compound 2 complex, and (e and f) COX1–aspirin complex.

achieving a probability of over 70%, which reflects the confidence level of the predictions (confidence score). The toxicity endpoints, pharmacokinetic parameters, median lethal dose, and toxicity classification for both compounds are summarized in Table 5.

Cytochrome P450 (CYP) is a family of enzymes essential for the metabolism of drugs and various other compounds. Six isoforms—CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, and CYP2E1—are primarily responsible for metabolizing most approved pharmaceuticals. Drug interactions involving these CYP enzymes can profoundly affect both the efficacy and safety of medications, potentially leading to adverse reactions or reduced therapeutic effectiveness. Such interactions can result in the premature discontinuation of drug development or the withdrawal of products from the market due to safety concerns.³⁷ From Table 5, we observed that both compounds are non-inhibitors of CYP2D6, CYP1A2, CYP2C19, CYP3A4, and CYP2E1, while acting as inhibitors of CYP2C9.

Hepatotoxicity refers to liver damage caused by chemical substances, such as medications, herbal supplements, and industrial chemicals.³⁸ Based on hepatotoxicity assessments, neither of the compounds is considered toxic to the liver. Carcinogenicity refers to the ability of a substance to induce cancer. A substance may be either active and carcinogenic or inactive



Fig. 7 2D and 3D representations summarize the results of the interaction analysis for the (a and b) COX2–compound 1 complex, (c and d) COX2–compound 2 complex, and (e and f) COX2–aspirin complex.

and considered safe.³⁹ According to computational estimations, both compounds are classified as inactive and safe, posing no cancer risk. Cytotoxicity describes a substance's capacity to damage or kill cells.⁴⁰ Based on cytotoxicity predictions, both compounds are deemed nontoxic to cells. Mutagenicity refers to the potential of a substance to cause genetic mutations in DNA. A substance may be active and mutagenic or inactive and nonmutagenic.⁴¹ Predictions indicate that both compounds are inactive, non-mutagenic, and genetically safe, with no potential to cause genetic mutations in DNA. Immunotoxicity refers to the harmful effects of substances on the immune system.⁴² According to the prediction table, both compounds are shown to be active against the immune system and may potentially cause adverse effects. The median lethal dose (LD₅₀, mg kg⁻¹) is the dose required to cause death in 50% of the tested animals. According to the Globally Harmonized System (GHS), substances are classified into six toxicity classes: Class I (LD₅₀ \leq 5) is fatal if swallowed; Class II ($5 < LD_{50} \leq 50$) is also fatal if swallowed; Class III ($50 < LD_{50} \leq 300$) is toxic if swallowed; Class IV ($300 < LD_{50} \leq 2000$) is harmful if swallowed; Class V ($2000 < LD_{50} \leq 5000$) may be harmful if swallowed; and Class VI ($LD_{50} > 5000$) is considered non-toxic.⁴³ Based on the prediction study, aurasperone B has an LD₅₀ of 1000 mg kg⁻¹, while ergosterol has an LD₅₀ of 10 mg kg⁻¹. Consequently, aurasperone B is classified as Class IV, and ergosterol is classified as Class II.

Table 5 Pharmacokinetics properties, toxicity properties, median lethal dose (LD_{50}), and toxicity class of aurasperone B and ergosterol

Parameters	Aurasperone B	Ergostero	
Pharmacokinetics parameter	rs		
CYP1A2	Inactive	Inactive	
CYP2C19	Inactive	Inactive	
CYP2C9	Active	Active	
CYP2D6	Inactive	Inactive	
CYP3A4	Inactive	Inactive	
CYP2E1	Inactive	Inactive	
Toxicity endpoints propertie	S		
Hepatotoxicity	Inactive	Inactive	
Carcinogenicity	Inactive	Inactive	
Immunotoxicity	Active	Active	
Mutagenicity	Inactive	Inactive	
Cytotoxicity	Inactive	Inactive	
Median lethal dose (LD ₅₀ , m	ng kg ^{−1})		
Predicted LD ₅₀	2000	10	
Predicted toxicity class	4	2	

4. Conclusion

In this study, we successfully isolated two secondary metabolites belonging to the bis or dimer NyPs and sterol classes from A. ficuum for the first time. Additionally, we present the 2D NMR data of aurasperone B for the first time. Both compounds were evaluated for their in vivo pharmacological potential. Ergosterol exhibited moderate pharmacological effects compared to aurasperone B in anti-inflammatory and analgesic studies. The molecular docking results support these experimental findings. The prediction study found that both compounds act as CYP2C9 inhibitors but are non-inhibitors of CYP2D6, CYP1A2, CYP2C19, CYP3A4 and CYP2E1. Furthermore, aurasperone B has an LD_{50} of 1000 mg kg⁻¹, whereas ergosterol has an LD_{50} of 10 mg kg⁻¹. As a result, aurasperone B is classified as Class IV, and ergosterol is classified as Class II. Both compounds are inactive and considered safe regarding carcinogenicity, cytotoxicity, mutagenicity, and hepatotoxicity, but they are active concerning their effects on the immune system. Given their modes of action, biological activities, and structure-activity relationships, bis-NyPs require further investigations. This study lays a solid foundation for the development of more potent pharmaceuticals with promising applications in both food and medicine.

Data availability

The supporting data have already been included in the article's ESI.†

Author contributions

Zafar Ali Shah: conceptualization, formal analysis, investigation, and methodology; Khalid Khan: conceptualization, supervision, project administration, data curation, and resources; Tanzeel Shah: formal analysis, validation, and writing—review, and editing; Nasir Ahmad: formal analysis and software; Asad Khan: validation, investigation, and methodology.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors are grateful to the Department of Chemistry, Islamia College, Peshawar, KP, Pakistan, for the provision of all facilities needed to execute the project.

References

- 1 J. W. Blunt, B. R. Copp, R. A. Keyzers, M. H. Munro and M. R. Prinsep, *Nat. Prod. Rep.*, 2014, **31**, 160–258.
- 2 H. M. Zhang, C. X. Ju, G. Li, Y. Sun, Y. Peng, Y. X. Li, X. P. Peng and H. X. Lou, *Mar. Drugs*, 2019, **17**, 383.
- 3 L. de Souza Ferranti, M. H. P. Fungaro, F. P. Massi, J. da Silva, R. Penha, J. C. Frisvad, M. H. Taniwaki and B. T. Iamanaka, *Int. J. Food Microbiol.*, 2018, 268, 53–60.
- 4 Q. Carboué, M. Maresca, G. Herbette, S. Roussos, R. Hamrouni and I. Bombarda, *Biomolecules*, 2019, **10**, 29.
- 5 Y. M. Lee, M. J. Kim, H. Li, P. Zhang, B. Bao, K. J. Lee and J. H. Jung, *J. Mar. Biotechnol.*, 2013, **15**, 499–519.
- 6 C. Z. Wu, X. P. Peng, G. Li, Q. Wang and H. X. Lou, *Molecules*, 2022, 27, 2514.
- 7 C. A. Lindsay, A. D. Kinghorn and H. L. Rakotondraibe, *Phytochem.*, 2023, 209, 113638.
- 8 M. H. Abd El-Razek, A. H. El-Desoky, A. A. Elgahamy, S. M. Bata, T. A. Mohamed and M. E. Hegazy, *Nat. Prod. Res.*, 2024, 1–11.
- 9 A. B. Awad and C. S. Fink, J. Nutr, 2000, 130, 2127-2130.
- 10 Z. A. Shah, K. Khan, T. Shah, N. Ahmad, A. Muhammad and H. U. Rashid, *Sci. Rep.*, 2023, **13**, 17260.
- 11 Z. A. Shah, K. Khan, H. U. Rashid, T. Shah, M. Jaremko and Z. Iqbal, *BMC Microbiol.*, 2022, 22, 29512.
- 12 N. Ahmad, F. Subhan, N. Islam, M. Shahid, F. Rahman and K. Fawad, *Arch. Pharm.*, 2017, **350**, e201600365.
- 13 M. Shahid, F. Subhan, N. Ahmad and R. D. Sewell, *Biomed. Pharmacother.*, 2017, **95**, 1725–1733.
- M. Miciaccia, B. D. Belviso, M. Iaselli, G. Cingolani,
 S. Ferorelli, M. Cappellari, P. Loguercio Polosa,
 M. G. Perrone, R. Caliandro and A. Scilimati, *Sci. Rep.*, 2021, 11, 4312.
- 15 S. W. Rowlinson, J. R. Kiefer, J. J. Prusakiewicz, J. L. Pawlitz, K. R. Kozak, A. S. Kalgutkar, W. C. Stallings, R. G. Kurumbail and L. J. Marnett, *J. Biol. Chem.*, 2003, **278**, 45763–45769.
- 16 W. Tian, C. Chen, X. Lei, J. Zhao and J. Liang, *Nucleic Acids Res.*, 2018, **46**, W363–W367.
- 17 J. Eberhardt, D. Santos-Martins, A. F. Tillack and S. Forli, *J. Chem. Inf. Model.*, 2021, **61**, 3891–3898.
- 18 S. Dallakyan and A. J. Olson, J. Chem. Biol., 2015, 243-250.
- 19 V. A. Dixit, Toxicol., 2019, 8, 157-171.

- 20 R. Khezri, S. Jamaleddin Shahtaheri, E. Khezri, M. Niknam Shahrak and M. Khadem, *Toxicol. Mech. Methods*, 2024, 1– 20.
- 21 N. Bouras, F. Mathieu, Y. Coppel and A. Lebrihi, *Nat. Prod. Rep.*, 2005, **19**, 653–659.
- 22 E. Endress, S. Bayerl, K. Prechtel, C. Maier, R. Merkel and T. M. Bayerl, *Langmuir*, 2002, **18**, 3293–3299.
- 23 M. A. Ernst-Russell, C. Chai, J. H. Wardlaw and J. A. Elix, *J. Nat. Prod.*, 2000, **63**, 129–131.
- 24 M. H. ElNaggar, G. M. Abdelwahab, O. Kutkat, M. GabAllah, M. A. Ali, M. E. El-Metwally, A. M. Sayed, U. R. Abdelmohsen and A. T. Khalil, *Mar. Drugs*, 2022, 20, 179.
- 25 H. Tanaka, P. L. Wang and O. Yamada, *Agric. Biol. Chem.*, 1966, **30**, 107–113.
- 26 G. Y. Lee, D. S. Jang, Y. M. Lee, J. M. Kim and J. S. Kim, *Arch. Pharmacal Res.*, 2006, **29**, 587–590.
- 27 S. Lu, J. Tian, W. Sun, J. Meng, X. Wang, X. Fu, A. Wang, D. Lai, Y. Liu and L. Zhou, *Molecules*, 2014, **19**, 7169–7188.
- 28 S. Ghosal, K. Biswas, D. Chakrabarti and F. Chemistry, J. Agric. Food Chem., 1979, 27, 1347–1351.
- 29 S. Merdivan and U. Lindequist, *Int. J. Med. Mushrooms.*, 2017, **19**, 93–105.
- 30 V. N. Zhabinskii, P. Drasar and V. A. Khripach, *Molecules*, 2022, **27**, 2103.

- 31 A. S. Leutou, K. Yun and B. W. Son, *Arch Pharm Res.*, 2016, **39**, 806–810.
- 32 A. Siriwardane, N. S. Kumar, L. Jayasinghe and Y. Fujimoto, *Nat. Prod. Res.*, 2015, **29**, 1384–1387.
- 33 W. Fang, X. Lin, J. Wang, Y. Liu, H. Tao and X. Zhou, *Molecules*, 2016, 21, 941.
- 34 H. Priestap, Tetrahedron, 1984, 40, 3617-3624.
- 35 M. Shaaban, K. A. Shaaban and M. S. Abdel-Aziz, Org. med. Chem. letters., 2012, 2, 1–8.
- 36 C. S. Williams, M. Mann and R. N. DuBois, *Oncogene*, 1999, 18, 7908–7916.
- 37 S. Dhillon and K. Gill, Clin. Pharmacokinet., 2006, 1-44.
- 38 A. Singh, T. Bhat and O. Sharma, J. Clin. Toxicol., 2011, 4, 2161–0495.
- 39 D. C. Wolf, S. M. Cohen, A. R. Boobis, V. L. Dellarco, P. A. Fenner-Crisp, A. Moretto, T. P. Pastoor, R. S. Schoeny, J. G. Seed and J. E. Doe, *Regul. Toxicol. Pharmacol.*, 2019, 103, 86–92.
- 40 O. A. Peters, Int Endod J., 2013, 46, 195–197.
- 41 K. K. Słoczyńska, B. Powroźnik, E. Pękala and A. M. Waszkielewicz, J. Appl. Genet., 2014, 55, 273–285.
- 42 B. Zerdan, S. Moussa, A. Atoui and H. Assi, *Int. J. Mol. Sci.*, 2021, **22**, 8242.
- 43 T. T. V. Tran, A. Surya Wibowo, H. Tayara and K. T. Chong, J. Chem. Inf. Model., 2023, 63, 2628–2643.